Experts say it's unlikely there will be widespread distribution of a vaccine this calendar year, however.
Also this week, Novartis announced it plans to make a gene-based coronavirus vaccine, which is in development at the Massachusetts Eye and Ear hospital, the Massachusetts General Hospital and the University of Pennsylvania.
The Maryland-based biotechnology company Novavax said it's launched preliminary clinical trials of its coronavirus vaccine candidate. The first results, on whether the drug is safe and effective, could be released as soon as July. The company aims to provide vaccines for those on the front lines of the COVID-19 pandemic: health care workers.
"If our phase two data support the safety and immunogenicity that we hope it will and we're able to see a signal for efficacy, it's possible that that first line would be vaccinated sometime in the fourth quarter of this year," Stanley Erck, CEO of Novavax told
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Novartis to make U.S. researchers' COVID-19 gene therapy vaccine hopefulNovartis re-entered vaccine making on Thursday, inking a manufacturing deal with a U.S. team whose COVID-19 candidate relies on technology similar to that of the Swiss drugmaker's $2.1 million-per-patient gene therapy, Zolgensma.
続きを読む »
Watch Healthy Returns: The path forward with IAVI CEO Dr. Mark FeinbergCan Ebola vaccine technology be used to combat Covid-19? MegTirrell interviews Dr. Mark Feinberg about IAVI's research and partnership with Merck.
続きを読む »
Moderna rally loses steam over COVID-19 vaccine worriesShares of biotechs racing to make coronavirus vaccines, including Moderna Inc , fell about 10% on Wednesday, as investor concerns grew about the prospects of the experimental products that are still in early stages of development.
続きを読む »
Column: Developing a coronavirus vaccine should not be rushed. Here's whyHistory tells us that rushing a vaccine for COVID-19 will prove more hazardous than if it's done right.
続きを読む »
Novartis Inks Deal to Make Experimental Coronavirus VaccineSwiss drugmaker will make a gene-based Covid-19 vaccine being developed by researchers at Massachusetts Eye and Ear hospital, Massachusetts General Hospital and the University of Pennsylvania.
続きを読む »
Why virus stocks are driving market volatilityOne cold, hard fact for retail investors: Vaccines have never been big moneymakers for pharmaceutical companies, and the ones that do make it to the market have historically taken between five to seven years to develop
続きを読む »